Lobe Sciences Ltd. (LOBEF)

USD 0.0

(-77.67%)

Market Cap (In USD)

394.58 Thousand

Revenue (In USD)

840.53 Thousand

Net Income (In USD)

-4.7 Million

Avg. Volume

31.35 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
8.0E-4-0.018
PE
-
EPS
-
Beta Value
2.286
ISIN
CA53946V2066
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Frederick D. Sancilio M.S., Ph.D.
Employee Count
-
Website
https://www.lobesciences.com
Ipo Date
2023-08-24
Details
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.